Dr. Maughan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1950 Circle of Hope
Clinic 2B
Salt Lake City, UT 84112Phone+1 801-585-0100Fax+1 801-585-0721
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2013 - 2016
- University of Utah HealthResidency, Internal Medicine, 2010 - 2013
- University of Kentucky College of MedicineClass of 2010
Certifications & Licensure
- UT State Medical License 2011 - 2026
- MD State Medical License 2013 - 2017
- ID State Medical License 2004 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer Start of enrollment: 2019 Nov 20
- Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2020 Aug 25
Publications & Presentations
PubMed
- Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma.Nicolas Sayegh, Yeonjung Jo, Georges Gebrael, Nishita Tripathi, Beverly Chigarira
Clinical Genitourinary Cancer. 2025-02-01 - Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial Carcinoma.Eleni Gamvroulas, Erin Bailey, Erik Harrington, Emma Jones, Rebecca Martin
Clinical Genitourinary Cancer. 2025-02-01 - Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).Benjamin L Maughan, Yanfang Liu, Suneel Mundle, Xiayi Wang, Mehregan Nematian-Samani
Prostate Cancer and Prostatic Diseases. 2024-12-20
Press Mentions
- Radium-223 plus Enzalutamide vs Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer - Benjamin MaughanMarch 9th, 2021
- Myovant’s Phase III Relugolix Trial’s Cardiovascular Event Reduction Trend InconclusiveJune 18th, 2020
- Gemcitabine, Cisplatin, plus Nivolumab in Patients with Muscle-Invasive Bladder Cancer with Selective Bladder SparingJune 15th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: